BioSpace News Archive

Lancets are a thin needle used to pierce the skin, primarily for diabetes. The lancet market is gaining popularity over the years and expected to grow at a staggering rate in the following years.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the appointment of Martijn Negen, MSc, MBA, as Vice President for Commercial Strategy.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test.

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India.

CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gene expression, announced that it has raised $45 million to propel the next phase of its scientific strategy, significantly expand its platform and advance multiple preclinical RNA therapies into human testing.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs.

Autolus Therapeutics plc announced that it has received innovative licensing and access pathway designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO1, the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory adult B-cell Acute Lymphocytic Leukemia in patients 18 years and older.

ITM AG, a leading radiopharmaceutical biotech company, announced the appointment of Dr. Klaus Maleck to its leadership team as Chief Financial Officer of the ITM Group.

RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed Gary Boddington to the board of directors.

Palisade Bio, Inc. today announced the launch of its Clinical Steering Committee (CSC) designed to provide strategic guidance over late-stage clinical program development for its lead investigational drug, LB1148.